drugset / Trial / NCT01505491

Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects

NCT01505491

Phase 1 Completed 193 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial will investigate the pharmacokinetics, safety and tolerability of BI 695501 and to establish pharmacokinetic equivalence of BI 695501 to adalimumab.

Timeline

Start
2011-12-01
Primary completion
2012-07-01
Completion
2012-07-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adalimumab Monoclonal antibody 40 mg Subcutaneous
Subject BI 695501 Monoclonal antibody Subcutaneous

Indications

No indication recorded.